[HTML][HTML] When the same treatment has different response: The role of pharmacogenomics in statin therapy
E Zheng, P Madura, J Grandos, M Broncel… - Biomedicine & …, 2024 - Elsevier
Statins, also known as HMG-CoA reductase inhibitors, are one of the most potently
prescribed and thoroughly researched medications, predominantly utilized for managing …
prescribed and thoroughly researched medications, predominantly utilized for managing …
Pharmacogenomics variability of lipid-lowering therapies in familial hypercholesterolemia
The exponential expansion of genomic data coupled with the lack of appropriate clinical
categorization of the variants is posing a major challenge to conventional medications for …
categorization of the variants is posing a major challenge to conventional medications for …
The SNPs rs429358 and rs7412 of APOE gene are association with cerebral infarction but not SNPs rs2306283 and rs4149056 of SLCO1B1 gene in southern …
H Wu, Q Huang, Z Yu, H Wu, Z Zhong - Lipids in Health and Disease, 2020 - Springer
Abstract Background Apolipoprotein E (ApoE) and solute carrier organic anion transporter
family member 1B1 (SLCO1B1) regulate lipid metabolism. However, the relationship …
family member 1B1 (SLCO1B1) regulate lipid metabolism. However, the relationship …
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance
M Bigossi, C Maroteau, AY Dawed… - European Heart …, 2023 - academic.oup.com
Background and aims The efficacy of statin therapy is hindered by intolerance to the therapy,
leading to discontinuation. Variants in SLCO1B1, which encodes the hepatic transporter …
leading to discontinuation. Variants in SLCO1B1, which encodes the hepatic transporter …
APOE gene ɛ4 allele (388C‐526C) effects on serum lipids and risk of coronary artery disease in southern Chinese Hakka population
Q Liu, H Wu, Z Yu, Q Huang… - Journal of Clinical …, 2021 - Wiley Online Library
Objective To analyze the relationship of Apolipoprotein E (APOE) and solute carrier organic
anion transporter family member 1B1 (SLCO1B1) gene polymorphisms with coronary artery …
anion transporter family member 1B1 (SLCO1B1) gene polymorphisms with coronary artery …
Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response
G Stillemans, A Paquot, GG Muccioli… - Clinical and …, 2022 - Wiley Online Library
The purpose of this study was to investigate the potential clinical relevance of estimating the
apparent clearance (CL/F) of atorvastatin through population pharmacokinetic (PopPK) …
apparent clearance (CL/F) of atorvastatin through population pharmacokinetic (PopPK) …
Prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with coronary heart …
T Wang, L Sun, L Xu, T Zhao, J Feng, L Yu… - Lipids in Health and …, 2021 - Springer
Background Dyslipidemia is a predisposing factor for coronary heart disease (CHD). High-
intensity statin therapy is recommended as secondary prevention. ABCB1 and SLCO1B1 …
intensity statin therapy is recommended as secondary prevention. ABCB1 and SLCO1B1 …
Simultaneous determination of the combined and free concentrations of atorvastatin and its major metabolite in vitro and in vivo based on ultrafiltration coupled with …
MC Cao, X Huang, BH Tang, HY Shi… - Frontiers in …, 2024 - frontiersin.org
A rapid, accurate and specific ultrafiltration with ultra performance liquid chromatographic-
tandem mass spectrometry method has been validated for the simultaneous determination …
tandem mass spectrometry method has been validated for the simultaneous determination …
Associations Between the Polymorphisms in the Coding Sequence of SLCO1B1 and Blood Lipid Levels Before and After Treatment by Atorvastatin in the Chinese …
C Chen, Y Tian, F Jia, M Feng, G Zhang… - Pharmacogenomics …, 2024 - Taylor & Francis
Purpose Atorvastatin is commonly used to treat dyslipidemia; however, individual responses
vary considerably. This study endeavors to evaluate the relationship between …
vary considerably. This study endeavors to evaluate the relationship between …
CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin
JW Park, JM Kim, HY Lee, J Noh, KA Kim, JY Park - Pharmaceutics, 2022 - mdpi.com
There is a large variability in individual responses to atorvastatin administration. This study
assessed the pharmacogenetic effects of solute carrier organic anion transporter family …
assessed the pharmacogenetic effects of solute carrier organic anion transporter family …